EVOTEQ And DAF Partnership To Combat Counterfeit Drugs In Egypt

In an era where counterfeit drugs pose a deadly threat and supply chain disruptions can mean life or death, EVOTEQ and Digital Access to Finance (DAF) have set their sights on a game-changing solution for Egypt's pharmaceutical industry.

Announced on the third day of Arab Health 2025, their newly signed partnership will introduce advanced track-and-trace technology to the Egyptian healthcare sector—an ambitious step toward eliminating fake medications, preventing shortages, and ensuring every patient gets access to safe, authenticated treatments.

This collaboration extends EVOTEQ's legacy of revolutionizing healthcare traceability in the UAE and now positions Egypt as the next frontier for secure, transparent, and efficient pharmaceutical supply chains.

For years, counterfeit medicines have flooded global markets, with the WHO estimating that nearly 10% of medical products in low- and middle-income countries are fake or substandard. Egypt—one of the region's largest pharmaceutical markets—has long sought a bulletproof system to authenticate, monitor, and regulate every pill and vial that enters its supply chain.

This is where EVOTEQ and DAF step in.
- End-to-End Traceability – Every drug in the Egyptian market will have a digital footprint, allowing authorities to track its journey from manufacturing to patient use.
- Enhanced Patient Safety – The system will eliminate fake medicines, ensuring that only approved, high-quality drugs reach consumers.
- Supply Chain Optimization – Hospitals, pharmacies, and regulators can detect and prevent shortages before they happen.
- Scalability Across MENA and Africa – Once fully implemented in Egypt, the model is set to expand regionally, redefining pharmaceutical regulation in MENA and beyond.

"This partnership reflects our commitment to adopting world-class innovations that safeguard patient health and strengthen Egypt's healthcare ecosystem," said Eng. Hatem Kandeel, Founder and Managing Director of DAF.

EVOTEQ has already proven the power of healthcare traceability in the UAE, where its solutions have been instrumental in combating counterfeit drugs and building supply chain resilience.

Now, in partnership with DAF Egypt, the goal is to replicate and scale that success across Egypt's 100-million-strong population—and eventually throughout the MENA region and Africa.

"Our collaboration with DAF Egypt is more than a partnership; it's a shared mission to elevate healthcare standards and protect lives," said Jihad Tayara, CEO of EVOTEQ.

The Egyptian Drug Authority (EDA) will now have unprecedented oversight and control, ensuring that every medication that enters the market is verified, safe, and available when needed.

This Memorandum of Understanding (MoU) isn't just about Egypt—it's about setting a new standard for pharmaceutical security across MENA and Africa.
With Egypt leading the charge, other nations in the region are likely to follow, positioning EVOTEQ and DAF as the go-to service providers for pharmaceutical regulation.
This isn't just an upgrade to healthcare logistics—it's a fundamental shift in how medicines are tracked, distributed, and secured.
And with EVOTEQ's expertise in secure supply chain technology and DAF's deep-rooted regulatory knowledge, this partnership isn't just an alliance.
It's the future of global medicine traceability.